Bladder perfusion pharmaceutical composition, preparation method therefor and application thereof
US-2024398841-A1 · Dec 5, 2024 · US
US9272033B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9272033-B2 |
| Application number | US-91208506-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 19, 2006 |
| Priority date | Apr 19, 2005 |
| Publication date | Mar 1, 2016 |
| Grant date | Mar 1, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides compositions for preventing or treating kidney disease comprising vitamin E, vitamin C, and a carotenoid and methods for preventing and treating kidney disease comprising administering such compositions to an animal susceptible to or suffering from kidney disease. In a preferred embodiment, the composition is admixed with one or more food ingredients to produce a food composition useful for preventing or treating kidney disease.
Opening claim text (preview).
What is claimed is: 1. A food composition comprising vitamin E, vitamin C, and a carotenoid in amounts sufficient for preventing or treating kidney disease, wherein the vitamin E is in an amount of from about 30 to about 1200 IU/kg, the vitamin C is in an amount of from about 0.01 to about 350 ppm vitamin C, and the carotenoid is in an amount from about 0.01 to about 3.5 ppm. 2. The composition of claim 1 comprising vitamin E, vitamin C, and a carotenoid in amounts sufficient to administer to a patient from at least 30 to 1200 IU/kg vitamin E, from at least 0.01 to 350 ppm vitamin C, and from at least 0.01 to 350 ppm carotenoid, wherein the patient is a canine or a feline. 3. The composition of claim 1 wherein the carotenoid is beta-carotene. 4. The composition of claim 1 further comprising one or more renal drugs. 5. The composition of claim 4 wherein the renal drug is selected from the group consisting of Converting Enzyme (ACE) inhibitors, androgens, erythropoietin, angiotensin, endothelin, angiotensin converting enzyme inhibitors, calcium channel blockers, H2 receptor antagonists, proton pump blockers, and calcitrol. 6. The composition of claim 1 further comprising one or more food ingredients. 7. The composition of claim 6 wherein the food ingredient is selected from the group consisting of fats, carbohydrates, proteins, fibers, and nutritional balancing agents. 8. The composition of claim 6 containing food ingredients in amounts from about 2% to about 50% fat, from about 0% to about 75% carbohydrate, from about 0% to about 95% protein, from about 0% to about 40% dietary fiber, and from about 0% to about 15% of one or more nutritional balancing agents. 9. The composition of claim 6 further comprising one or more renal drugs. 10. The composition of claim 9 wherein the renal drug is selected from the group consisting of Converting Enzyme (ACE) inhibitors, androgens, erythropoietin, angiotensin, endothelin, angiotensin converting enzyme inhibitors, calcium channel blockers, H2 receptor antagonists, proton pump blockers, and calcitrol.
Related publications grouped by family.
Answers are generated from the same data shown on this page.